

Melissa J Rose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7186922/publications.pdf>

Version: 2024-02-01

28
papers

521
citations

840776

11
h-index

677142

22
g-index

28
all docs

28
docs citations

28
times ranked

658
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating the safety and feasibility of osteopathic medicine in the pediatric oncology outpatient setting. <i>Journal of Osteopathic Medicine</i> , 2022, .	0.8	0
2	Supportive care and osteopathic medicine in pediatric oncology: perspectives of current oncology clinicians, caregivers, and patients. <i>Supportive Care in Cancer</i> , 2021, 29, 1121-1128.	2.2	4
3	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. <i>Human Mutation</i> , 2021, 42, 1367-1383.	2.5	11
4	Diagnostic workâ€up for severe aplastic anemia in children: Consensus of the <sc>North American Pediatric Aplastic Anemia Consortium</sc>. <i>American Journal of Hematology</i> , 2021, 96, 1491-1504.	4.1	14
5	Characterization of the severe phenotype of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2020, 95, E281.	4.1	8
6	A Preteen Female with Fatigue and Incidental Finding of Thrombocytopenia. , 2020, , 151-160.		0
7	Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice. <i>Blood Advances</i> , 2019, 3, 1907-1915.	5.2	26
8	A novel <i>SAMD9</i> variant identified in patient with MIRAGE syndrome: Further defining syndromic phenotype and review of previous cases. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27726.	1.5	15
9	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	4.1	37
10	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. <i>Haematologica</i> , 2019, 104, e51-e53.	3.5	46
11	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. <i>Blood</i> , 2019, 134, 949-949.	1.4	0
12	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. <i>Blood</i> , 2019, 134, 2175-2175.	1.4	0
13	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	4.1	30
14	Matched unrelated donor transplantation in glycogen storage disease type 1b patient corrects severe neutropenia and recurrent infections. <i>Bone Marrow Transplantation</i> , 2018, 53, 1076-1078.	2.4	9
15	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. <i>Blood</i> , 2018, 131, 2183-2192.	1.4	121
16	Pklr Intron Splicing-Associated Mutations and Alternate Diagnoses Are Common in Pyruvate Kinase Deficient Patients with Single or No Pklr Coding Mutations. <i>Blood</i> , 2018, 132, 3607-3607.	1.4	4
17	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2018, 132, 4807-4807.	1.4	1
18	Exploring the Value of Just-in-Time Teaching as a Supplemental Tool to Traditional Resident Education on a Busy Inpatient Pediatrics Rotation. <i>Academic Pediatrics</i> , 2017, 17, 589-592.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). <i>Blood</i> , 2017, 130, 752-752.	1.4	2
20	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2016, 388, 45-54.	13.7	116
21	A Comparison of Resource Utilization, Cost and Mortality in Children Treated for Severe Aplastic Anemia. <i>Blood</i> , 2016, 128, 2333-2333.	1.4	5
22	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. <i>Blood</i> , 2016, 128, 1008-1008.	1.4	0
23	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 4752-4752.	1.4	0
24	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. <i>Blood</i> , 2015, 126, 3337-3337.	1.4	4
25	Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2015, 126, 3467-3467.	1.4	2
26	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. <i>Blood</i> , 2015, 126, 2136-2136.	1.4	1
27	Inhaled Nitric Oxide Decreases Leukocyte Trafficking in the Neonatal Mouse Lung During Exposure to >95% Oxygen. <i>Pediatric Research</i> , 2010, 67, 244-249.	2.3	16
28	Congenital amegakaryocytic thrombocytopenia: The diagnostic importance of combining pathology with molecular genetics. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1263-1265.	1.5	37